Moritz Binder

102PUBLICATIONS
222CO-AUTHORS
Haematological tumoursPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical mycologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (102)

|Sep 12, 2026
Prophylactic dexamethasone at the time of absolute lymphocyte expansion does not mitigate risk or event-free survival for immune effector cell associated delayed neurotoxicity.

|Aug 25, 2026
Chromosome 1q Gain Defines a Plasma Cell-Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival.

|Aug 20, 2026
Malignant B-cell States Orchestrate Spatially Organized Immune Ecosystems in B-cell Lymphomas.

|Aug 03, 2026
High prevalence of iron deficiency among daratumumab-treated newly diagnosed multiple myeloma patients.

|Jul 27, 2026
Predictors of post-transplant measurable residual disease negativity and impact on clinical outcomes in multiple myeloma.

|Jul 27, 2026
Self-Reported Geriatric Impairments and Treatment Toxicity in Older Patients with Multiple Myeloma-A Single Center Prospective Study.

Pageof 17

Frequent Collaborators

70 joint publications

Shaji Kumar

63 joint publications

Taxiarchis V Kourelis

59 joint publications

Angela Dispenzieri

58 joint publications

Morie Gertz